Ana Gorgulho1, Ana Maria Grilo2, Manuel de Figueiredo3, Joana Selada4. 1. MD, Internal Medicine Trainee, Internal Medicine Department, Hospital de Cascais, 2755-009, Alcabideche, Cascais. Portugal. 2. MD, Internal Medicine Specialist, Internal Medicine Department, Hospital de Cascais, 2755-009, Alcabideche, Cascais. Portugal. 3. MD, Internal Medicine and Intensive Medicine Specialist, Local Group Coordinator for Prevention and Control of Infection and Antimicrobial Resistance, Hospital de Cascais, 2755-009, Alcabideche, Cascais. Portugal. 4. MD, Clinical Pathology Specialist, Microbiology Laboratory, SynLab, Hospital de Cascais, 2755-009, Alcabideche, Cascais. Portugal.
Abstract
BACKGROUND: Our hospital experienced an outbreak of OXA-48-producing Enterobacteriaceae, triggering this study. We aimed to describe the population with carbapenemase-producing Enterobacteriaceae (CPE) in our hospital from 2014 to 2018, the phenotypic and genotypic characteristics of isolates, and strategies to stop the outbreak. METHODS: We performed a retrospective study, including every patient with CPE species in a clinical sample. Epidemiology, risk factors, treatment and outcomes were gathered from medical records. RESULTS: A total 113 patients were included, ranging from 5 in 2015 to 83 in 2018. In 2018 the number of CPE went from 4 in May to 20 in July. With the implemented measures, propagation stopped. Implantable devices were present in 36% of patients and open wounds in 34%. Antibiotics had been prescribed to 71% of patients in the prior 30 days and most of the patients had been hospitalized for more than 5 days prior to sample collection or had a hospital stay in the previous year.Klebsiella pneumoniae was the most common species (87%). OXA-48 (62%) and Klebsiella pneumoniae-carbapenemase (KPC) (15%) were the most common carbapenemases, with OXA-48 being implicated in the 2018 outbreak. The case fatality rate at 30 days was 32%. Combination therapy resulted in less mortality. CONCLUSIONS: While KPC is the most common carbapenemase in Europe and Portugal, we experienced an important OXA-48 outbreak. Surveillance should be in place as these isolates are probably spreading. Effective communication, multidisciplinary team work and proper infection control measures are some of the best strategies during outbreaks. GERMS.
BACKGROUND: Our hospital experienced an outbreak of OXA-48-producing Enterobacteriaceae, triggering this study. We aimed to describe the population with carbapenemase-producing Enterobacteriaceae (CPE) in our hospital from 2014 to 2018, the phenotypic and genotypic characteristics of isolates, and strategies to stop the outbreak. METHODS: We performed a retrospective study, including every patient with CPE species in a clinical sample. Epidemiology, risk factors, treatment and outcomes were gathered from medical records. RESULTS: A total 113 patients were included, ranging from 5 in 2015 to 83 in 2018. In 2018 the number of CPE went from 4 in May to 20 in July. With the implemented measures, propagation stopped. Implantable devices were present in 36% of patients and open wounds in 34%. Antibiotics had been prescribed to 71% of patients in the prior 30 days and most of the patients had been hospitalized for more than 5 days prior to sample collection or had a hospital stay in the previous year.Klebsiella pneumoniae was the most common species (87%). OXA-48 (62%) and Klebsiella pneumoniae-carbapenemase (KPC) (15%) were the most common carbapenemases, with OXA-48 being implicated in the 2018 outbreak. The case fatality rate at 30 days was 32%. Combination therapy resulted in less mortality. CONCLUSIONS: While KPC is the most common carbapenemase in Europe and Portugal, we experienced an important OXA-48 outbreak. Surveillance should be in place as these isolates are probably spreading. Effective communication, multidisciplinary team work and proper infection control measures are some of the best strategies during outbreaks. GERMS.
Authors: K M Cronin; Y S Poy Lorenzo; M E Olenski; A E Bloch; K Visvanathan; M J Waters; K L Buising Journal: J Hosp Infect Date: 2017-02-16 Impact factor: 3.926
Authors: Elliot L Rank; Thomas Lodise; Lisa Avery; Eve Bankert; Erica Dobson; Ghinwa Dumyati; Stephen Hassett; Marina Keller; Matthew Pearsall; Teresa Lubowski; Joseph J Carreno Journal: Open Forum Infect Dis Date: 2018-11-16 Impact factor: 3.835
Authors: Alma Brolund; Nina Lagerqvist; Sara Byfors; Marc J Struelens; Dominique L Monnet; Barbara Albiger; Anke Kohlenberg Journal: Euro Surveill Date: 2019-02
Authors: Marta Aires-de-Sousa; José Manuel Ortiz de la Rosa; Maria Luísa Gonçalves; Ana Luísa Pereira; Patrice Nordmann; Laurent Poirel Journal: Emerg Infect Dis Date: 2019-09 Impact factor: 6.883
Authors: Daniela Gonçalves; Pedro Cecílio; Alberta Faustino; Carmen Iglesias; Fernando Branca; Alexandra Estrada; Helena Ferreira Journal: Front Microbiol Date: 2021-12-14 Impact factor: 5.640